← Leaderboards
Christopher Emil Whitehead
Mekanistic Therapeutics, Llc
$1,292,843
Attributed
$2,585,686
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $973K · FY2017–22$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,585,686 · 3
By mechanism
R44$1,861,575 · 1
R41$724,111 · 2
Top collaborators
- Judith S Leopold5 shared
Others in their field
Other Emerging Leaders on “Survival Rate”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Phd, Stephen Schwartz · Fred Hutchinson Cancer Research Center$21,360,715
- Scarlett Lin-Gomez · University Of California, San Francisco$18,598,737
- Mary Charlton · University Of Iowa$16,748,573
- Lihua Liu · University Of Southern California$16,229,586
- Eric Durbin · University Of Kentucky$13,607,670
Research focus
Survival RateAntineoplastic AgentsPre-ClinicalSignal TransductionTumorFundingEffective TherapyPhosphotransferasesDoseSignaling MoleculeLeadEpidermal Growth Factor ReceptorEvaluationPublic Health1-Phosphatidylinositol 3-KinaseDesignOncogenicPathway InteractionsCancer PrognosisClinical TrialsBaseIn VitroClinical DevelopmentInvestments
Grant awards (5)
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers$149,608
R41 · FY2022 · CA · contact PI
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers$299,503
R41 · FY2021 · CA · contact PI
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$973,003
R44 · FY2020 · CA · contact PI
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$888,572
R44 · FY2019 · CA · contact PI
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$275,000
R41 · FY2017 · CA · contact PI